Safety of Bio-Interventional Uveoscleral Outflow Enhancement: Twelve-Month Post-Operative Results from 395 Eyes in the CREST Study

Purpose: To characterize 12-month ocular safety of bio-interventional uveoscleral outflow enhancement in open-angle glaucoma (OAG). Design: Prospective, multicenter real-world evidence study (CREST; NCT05506423 ). Participants: Adults with OAG treated by bio-interventional uveoscleral outflow enhancement with acellular scleral allograft spacers (AlloFlo™, Iantrek, Inc.), standalone or with phacoemulsification, reaching 12 months of follow-up. Methods: Adverse events were captured prospectively at each protocol-specified visit against pre-defined definitions; data were analyzed at the eye level. Main Outcome Measures: Pre-specified ocular safety endpoints: adverse events, clinically significant hypotony, sustained intraocular pressure (IOP) elevation ≥ 10 mmHg beyond 30 days, allograft migration, corneal endothelial decompensation, secondary incisional glaucoma surgery, and endothelial cell density. Results: Of 395 eyes (mean age 72.8 years; 52% female), 267 were combined with phacoemulsification (Cohort 1) and 128 standalone (Cohort 2). Medicated IOP decreased from 19.1 to 14.5 mmHg (p < 0.001) and medications from 1.9 to 1.2, with 42% medication-free. Sustained IOP elevation occurred in 34 eyes (8.6%), BCVA loss ≥ 2 lines in 15 (3.8%), hyphema > 2 mm in 6 (1.5%) and hypotony in 1 (0.3%). Two allograft spacers entered the anterior chamber in one eye and were successfully repositioned intraoperatively. Serious events occurred in 12 eyes (3.0%). In the N=91 eyes with paired specular microscopy data, endothelial cell density changed -6.5% (-8.7%, -4.4%). There were no reports of endothelial decompensation, endophthalmitis, or sympathetic ophthalmia. Conclusions: Through 12 months no endothelial decompensation, endophthalmitis or sympathetic ophthalmia occurred, and most events were self-limiting or medically managed. Endothelial cell loss tracked concurrent cataract surgery rather than the allograft, though that subgroup is small. Follow-up remains shorter than the interval over which an earlier supraciliary microstent diverged from controls.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-13
DOI
https://doi.org/10.64898/2026.11.12.26367928
Primary Topic
Glaucoma and retinal disorders
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Safety of Bio-Interventional Uveoscleral Outflow Enhancement: Twelve-Month Post-Operative Results from 395 Eyes in the CREST Study

Tsontcho Ianchulev, Douglas J. Rhee, Steven R. Sarkisian, Ticiana De Francesco et al.
8 links
medRxiv
Glaucoma and retinal disorders
preprint

Safety of Bio-Interventional Uveoscleral Outflow Enhancement: Twelve-Month Post-Operative Results from 395 Eyes in the CREST Study

Tsontcho Ianchulev, Douglas J. Rhee, Steven R. Sarkisian, Ticiana De Francesco, James Lewis, Kiper Nelson
preprint en

Abstract

Purpose: To characterize 12-month ocular safety of bio-interventional uveoscleral outflow enhancement in open-angle glaucoma (OAG). Design: Prospective, multicenter real-world evidence study (CREST; NCT05506423 ). Participants: Adults with OAG treated by bio-interventional uveoscleral outflow enhancement with acellular scleral allograft spacers (AlloFlo™, Iantrek, Inc.), standalone or with phacoemulsification, reaching 12 months of follow-up. Methods: Adverse events were captured prospectively at each protocol-specified visit against pre-defined definitions; data were analyzed at the eye level. Main Outcome Measures: Pre-specified ocular safety endpoints: adverse events, clinically significant hypotony, sustained intraocular pressure (IOP) elevation ≥ 10 mmHg beyond 30 days, allograft migration, corneal endothelial decompensation, secondary incisional glaucoma surgery, and endothelial cell density. Results: Of 395 eyes (mean age 72.8 years; 52% female), 267 were combined with phacoemulsification (Cohort 1) and 128 standalone (Cohort 2). Medicated IOP decreased from 19.1 to 14.5 mmHg (p < 0.001) and medications from 1.9 to 1.2, with 42% medication-free. Sustained IOP elevation occurred in 34 eyes (8.6%), BCVA loss ≥ 2 lines in 15 (3.8%), hyphema > 2 mm in 6 (1.5%) and hypotony in 1 (0.3%). Two allograft spacers entered the anterior chamber in one eye and were successfully repositioned intraoperatively. Serious events occurred in 12 eyes (3.0%). In the N=91 eyes with paired specular microscopy data, endothelial cell density changed -6.5% (-8.7%, -4.4%). There were no reports of endothelial decompensation, endophthalmitis, or sympathetic ophthalmia. Conclusions: Through 12 months no endothelial decompensation, endophthalmitis or sympathetic ophthalmia occurred, and most events were self-limiting or medically managed. Endothelial cell loss tracked concurrent cataract surgery rather than the allograft, though that subgroup is small. Follow-up remains shorter than the interval over which an earlier supraciliary microstent diverged from controls.

medRxiv
University of Utah (US), New York Eye and Ear Infirmary (US), Case Western Reserve University (US)
Good health and well-being
Glaucoma and retinal disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon